Minocycline restores striatal tyrosine hydroxylase in GDNF heterozygous mice but not in methamphetamine-treated mice

Neurobiology of Disease

Volumn 33, Issue 3, 2009, Pages 459-466

  Boger, Heather A ^a   Middaugh, Lawrence D ^a   Granholm, Ann Charlotte ^a   McGinty, Jacqueline F ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dopamine; Neuroinflammation; Neurotoxicity; Neurotrophins; Striatum; Substantia nigra; Transgenic mice

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; METHAMPHETAMINE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE P38; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LOCOMOTION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; BODY TEMPERATURE; CELL COUNT; CORPUS STRIATUM; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; METHAMPHETAMINE; MICE; MICE, TRANSGENIC; MICROGLIA; MINOCYCLINE; MOTOR ACTIVITY; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PHOTOMICROGRAPHY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 60849136010     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.11.013     Document Type: Article

References (52)

1. Ahuja M., Bishnoi M., and Chopra K. Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology 244 (2007) 111-122
2. Bantubungi K., Jacquard C., Greco A., Pintor A., Chtarto A., Tai K., Galas M.C., Tenenbaum L., Deglon N., Popoli P., Minghetti L., Brouillet E., Brotchi J., Levivier M., Schiffmann S.N., and Blum D. Minocycline in phenotypic models of Huntington's disease. Neurobiol. Dis. 18 (2005) 206-217
3. Bhat N.R., Zhang P., Lee J.C., and Hogen H.L. Extracellular signal-regulated kinase and p38 subgroups of MAP kinases regulate inducible nitric oxide synthase and tumor necrosis factor gene expression in endotoxin stimulated primary glial cultures. J. Neurosci. 18 (1998) 1633-1641
4. Boger H.A., Middaugh L.D., Huang P., Zaman V., Smith A.C., Hoffer B.J., Tomac A.C., and Granholm A.-Ch. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp. Neurol. 202 (2006) 336-347
5. Boger H.A., Middaugh L.D., Patrick K.S., Ramamoorthy S., Denehy E.D., Zhu H., Pacchioni A.M., Granholm A.-Ch., and McGinty J.F. Longterm consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J. Neurosci. 27 (2007) 8816-8825
6. Blum D., Chtarto A., Tenenbaum L., Brotchi J., and Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17 (2004) 359-366
7. Chen C.C., and Wang J.K. p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol. Pharmacol. 55 (1999) 481-488
8. Chen M., Ona V.O., Li M., Ferrant R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., and Friendlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
9. Choe E.S., and McGinty J.F. NMDA receptors and p38MAP kinase are required for cAMP-dependent CREB and Elk-1 phosphorylation in the striatum of rats. Neuroscience 101 (2000) 607-617
10. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., and Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5 (1996) 137-143
11. Diguet E., Fernagut P.O., Wei X., Du Y., Rouland R., Gross C., Bezard E., and Tison F. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci. 19 (2004) 3266-3276
12. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L.G., Luecke S., Phebus L.A., Bymaster F.P., and Paul S. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14669-14674
13. Fiedorowicz A., Figiel I., Kaminska B., Zaremba M., Wilk S., and Oderfeld-Nowak B. Dentate granule neuron apoptosis and glia activation in murine hippocampus induced by trimethyltin exposure. Brain Res. 912 (2001) 116-127
14. Francis J.W., Von Visger J., Markelonis G.J., and Oh T.H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 17 (1995) 7-12
15. Glicksman M.A., Chiu A.Y., Dionne C.A., Harty M., Kaneko M., Murakata C., Oppenheim R.W., Prevette D., Sengelaub D.R., Vaught J.L., and Neff N.T. CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. J. Neurobiol. 35 (1998) 361-370
16. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacAurthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., and Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6 (2007) 1045-1053
17. Halberda J.P., Middaugh L.D., Gard B.E., and Jackson B.P. DAD1- and DAD2-like agonist effects on motor activity of C57 mice: differences compared to rats. Synapse 26 (1997) 81-92
18. Hebert M.A., and O'Callaghan J.P. Protein phosphorylation cascades associated with methamphetamine-induced glial activation. Ann. N. Y. Acad. Sci. 914 (2000) 238-262
19. Hendricks B.S., Hua F., and Chabot J.R. Analysis of mechanistic pathway models in drug discovery: p38 pathway. Biotechnol. Prog. 24 (2008) 96-109
20. Hunter C.L., Quintero E.M., Gilstrap L., Bhat N.R., and Granholm A.-Ch. Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. Eur. J. Neurosci. 19 (2004) 3305-3316
21. Imam S.Z., Islam F., Itzhak Y., Slikker Jr. W., and Ali S. Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: implication for the prevention of methamphetamine-induced neurotoxic damage. Ann. N. Y. Acad. Sci. 914 (2000) 157-171
22. Jorgensen M.B., Finsen B.R., Jensen M.B., Castellano B., Diemer N.H., and Zimmer J. Microglial and astroglial reactions to ischemic and kainic acid-induced lesions of the adult rat hippocampus. Exp. Neurol. 120 (1993) 70-88
23. Kato H., Tanaka S., Oikawa T., Koike T., Takahashi A., and Itovama Y. Expression of microglial response factor-1 in microglia and macrophages following cerebral ischemia in the rat. Brain Res. 882 (2000) 206-211
24. Kawasaki H., Morooka T., Shimohama S., Kimura J., Hirano T., Gotoh Y., and Nishida E. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J. Biol. Chem. 272 (1997) 18518-18521
25. Kawasaki T., Ishihara K., Yukio A., Nakamura S., Itoh S., Baba A., and Matsuda T. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur. J. Pharmacol. 542 (2006) 92-99
26. Kriz J., Nguyen M.D., and Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 10 (2002) 268-278
27. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999) 598-605
28. Lavoie M.J., Card J.P., and Hastings T.G. Microglial activation preceded dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 187 (2004) 47-57
29. Lee J.C., Laydon J.T., McDonnel P.C., Gallagher T.F., Kumar S., Green D., McNulty D., Blumenthal M.J., Heys J.R., Landyatter S.W., Strickler J.E., McLaughlin M.M., Siemens I.R., Fisher S.M., Livi G.P., White J.R., Adams J.L., and Young P.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
30. LeWitt P.A., and Taylor D.C. Protection against Parkinson's disease: clinical experience. Neurotherapeutics 5 (2008) 210-225
31. Lowy M.T., Wittenberg L., and Yamamoto B.K. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J. Neurochem. 65 (1995) 268-274
32. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates: Deluxe Edition of the Atlas. Second ed. (2001), Academic Press, San Diego, CA, USA
33. Pichel J.G., Shen L., Sheng H.Z., Granholm A.-Ch., Drago J., Grinberg A., Lee E.J., Huang S.P., Saarma M., Hoffer B.J., Sariola H., and Westphal H. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382 (1996) 73-76
34. Quintero E.M., Willis L., Singleton R., Harris N., Huang P., Bhat N.R., and Granholm A.-Ch. Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res. 1093 (2006) 198-207
35. Scali C., Prosperi C., Giovannelli L., Bianchi L., Pepeu G., and Casamenti F. Beta(1-40) amyloid peptide injection into the nucleus basalis of rats induces microglia reaction and enhances cortical gamma-aminobutyric acid release in vivo. Brain Res. 831 (1999) 319-321
36. Sheng P., Cerruti C., and Cadet J.L. Methamphetamine (METH) causes reactive gliosis in vitro: attenuation by the ADP-ribosylation (ADPR) inhibitor, benzamide. Life Sci. 55 (1994) PL51-PL54
37. Sriram K., Miller D.B., and O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 96 (2006) 706-718
38. Staszewski R.D., and Yamamoto B.K. Methamphetamine-induced spectrin proteolysis in the rat striatum. J. Neurochem. 96 (2006) 1267-1276
39. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., and Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 367 (2004) 349-354
40. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., and Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 311 (2004) 1-7
41. Tikka T., and Koistinaho J. Minocycline provides neuroprotection against NMDA neurotoxicity by inhibiting microglia. J. Immunol. 166 (2001) 7527-7533
42. Tikka T., Fiebich B., Goldsteins G., Keinanen R., and Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21 (2001) 2580-2588
43. Tsuji M., Wilson M.A., Lange M.S., and Johnston M.V. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp. Neurol. 189 (2004) 58-65
44. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskava I.G., Cattaneo E., Ferrante R.J., Kristal B.S., and Friedlander R.M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10483-10487
45. Wang J., Wei Q., Wang C.Y., Hill W.D., Hess D.C., and Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in the mitochondria. J. Biol. Chem. 279 (2004) 19948-19954
46. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.-K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 22 (2002) 1763-1771
47. Yang L., Sugama S., Chirichigno J.W., Gregorio J., Lorenzl S., Shin D.H., Browne S.E., Shimizu Y., Joh T.H., Beal M.F., and Albers D.S. Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74 (2003) 278-285
48. Yenari M.A., Xu L., Tang X.N., Oiao Y., and Giffard R.G. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 37 (2006) 1087-1093
49. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., and Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15769-15774
50. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13496-13500
51. Zawada W.M., Meintzer M.K., Rao P., Marotti J., Wang X., Esplen J.E., Clarkson E.D., Freed C.R., and Heidenreich K.A. Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons. Brain Res. 891 (2001) 185-196
52. Zhu S., Stravroskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., and Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78